Replies to post #114007 on Innovation Pharmaceuticals Inc (IPIX)

[TOB]

Lol, everything is an opinion here.

What's your point? That being Up-listed is better? I don't disagree so how do our opinions differ? Perhaps my opinion is just less well known as I don't repeat it 5 times a day every day to snipe at the CEO of the company I'm invested in?

I'm also not convinced that up-listing is a final destination in heaven for CTIX. I know of exchange listed companies with trials in progress that trade for less than CTIX. The share price is just the balance between the buyers and the sellers at any given point in time, or period. I think it will be beneficially, but I'm making a prediction of the future which is at best an educated guess. What will bring the real money to CTIX shareholders is Clinical Trial success. So far no clinical trial failures. Great.

It is pretty well known that there was a large share transfer, and that those shares became unrestricted when the current decline started. It also looks like that selling has eased up as CTIX had a rally leg up from a sideways channel.

Would an up-list have absorbed those shares better? IMO yes, though I can't prove that. But as NASDAQ decided to use their discretion and wait for the 10-K, this was beyond CTIX management's control. (This is actually them following their rules and not doing something optional and discretionary to them)

Or is your argument there should have been a R/S? Good grief, what's the point of constantly repeating that moot point? The CEO has ruled out an R/S, his decision, like it or not. This is well known, so any shareholder who required a R/S had ample chance to sell, or never buy CTIX in the first place. Simple DD would reveal that the CEO has ruled out a R/S.

There is also ZERO proof that a R/S with an up-listing would equal a higher share price now. The market doesn't follow fixed rules, otherwise it would be easy to make money.

Regardless, IT IS A MOOT POINT AS IT HAS BEEN RULED OUT. Is that not clear? The CEO, or any of us, could also have bought some stock which in hindsight had quadrupled this year. Hooray for hindsight decisions and the endless discussion of moot points. Good grief.